三友医疗(688085) - 2022 Q3 - 季度财报

Key Financial Data Key Accounting Data and Financial Indicators The company reported 185 million Yuan in Q3 2022 operating revenue, up 17.18%, and 482 million Yuan year-to-date, up 15.00%, with total assets reaching 2.13 billion Yuan, indicating steady growth Key Financial Indicators for Q3 2022 and Year-to-Date | Indicator | Current Period (Q3 2022) (Yuan) | YoY Growth (%) | Year-to-Date (YTD Q3 2022) (Yuan) | YoY Growth (%) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 184,880,666.87 | 17.18% | 481,533,122.53 | 15.00% | | Net Profit Attributable to Parent Company Shareholders | 47,958,441.60 | 11.58% | 124,614,640.34 | 9.85% | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-recurring Items) | 37,043,784.32 | 0.40% | 108,814,184.34 | 21.15% | | Net Cash Flow from Operating Activities | Not applicable | Not applicable | 95,923,327.44 | 64.94% | | Basic EPS (Yuan/share) | 0.21 | 1.47% | 0.55 | 9.79% | | Total R&D Investment | 18,041,941.00 | 15.18% | 43,277,295.42 | 17.50% | Key Balance Sheet Indicators at Period End | Indicator | Current Period End (2022-09-30) (Yuan) | Prior Year End (2021-12-31) (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 2,130,134,940.92 | 1,997,170,041.73 | 6.66% | | Total Equity Attributable to Parent Company Shareholders | 1,773,545,023.25 | 1,685,852,121.86 | 5.20% | Non-recurring Gains and Losses and Their Amounts Non-recurring gains and losses totaled 10.91 million Yuan for the period and 15.80 million Yuan year-to-date, mainly from government grants and structured deposit income Key Non-recurring Gains and Losses (Year-to-Date) | Item | Year-to-Date Amount (Yuan) | Description | | :--- | :--- | :--- | | Government Grants Recognized in Current Profit or Loss | 11,803,526.35 | Government Grants | | Fair Value Change Gains and Losses from Transactional Financial Assets | 8,053,398.05 | Structured Deposit Income | | Income Tax Impact | -3,146,715.74 | - | | Impact on Minority Interests (After Tax) | -996,825.50 | - | | Total | 15,800,456.00 | - | Analysis of Changes in Key Financial Indicators Year-to-date, net cash flow from operating activities significantly increased by 64.94% year-on-year, primarily due to enhanced management of accounts receivable - Net cash flow from operating activities increased by 64.94% year-to-date, primarily due to enhanced management of accounts receivable[12] Shareholder Information Shareholding Status of Shareholders As of the reporting period end, the company had 8,874 common shareholders, with the top five holding over 60%, indicating a relatively concentrated equity structure, and Xu Nong, Michael Mingyan Liu, and David Fan acting in concert - At the end of the reporting period, the company had 8,874 common shareholders[14] Top Five Shareholders' Shareholding Status | Shareholder Name | Number of Shares Held | Shareholding Percentage (%) | | :--- | :--- | :--- | | QM5 LIMITED | 41,749,400 | 18.48 | | Xu Nong | 29,491,000 | 13.06 | | LIU Michael Mingyan | 24,439,800 | 10.82 | | Nantong Chenhong Economic Consulting Partnership | 21,560,000 | 9.55 | | FAN DAVID | 15,569,400 | 6.89 | - Among the top ten shareholders, Xu Nong, Michael Mingyan Liu, and David Fan signed a Concerted Action Agreement, forming a concerted action relationship[16] Other Significant Matters Business Operations Update During the reporting period, the company made significant progress in strategic investment, market access, and product R&D, including a strategic investment in French listed company Implanet, full bids in national centralized procurement for core spinal products, and NMPA approval for its looped titanium plate sports medicine product - The company made a strategic investment in French orthopedic listed company Implanet, paying the first installment of 2.5 million Euros, achieving a 28.96% stake and becoming its largest single shareholder, with the stake expected to reach 43.19% upon completion[17][18] - The company's main orthopedic spinal consumables products secured A-group bids in national centralized procurement, expected to expand hospital coverage, increase surgical volumes, and enhance market penetration[18] - Significant progress was made in sports medicine product R&D, with the looped titanium plate receiving registration approval from the National Medical Products Administration[19] Quarterly Financial Statements Consolidated Financial Statements As of September 30, 2022, consolidated total assets reached 2.13 billion Yuan, up 6.66% from year-start, with year-to-date operating revenue of 482 million Yuan and net cash flow from operating activities up 64.94%, reflecting healthy financials Consolidated Balance Sheet As of September 30, 2022, total assets reached 2.13 billion Yuan, a 6.66% increase from year-start, with current assets at 1.164 billion Yuan and non-current assets at 966 million Yuan; total equity attributable to parent company shareholders was 1.774 billion Yuan, up 5.20% Key Items from Consolidated Balance Sheet | Item | September 30, 2022 (Yuan) | December 31, 2021 (Yuan) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 387,912,275.90 | 382,307,456.00 | | Accounts Receivable | 271,255,224.07 | 248,862,670.47 | | Inventories | 143,260,453.55 | 121,477,550.04 | | Total Assets | 2,130,134,940.92 | 1,997,170,041.73 | | Accounts Payable | 164,458,529.82 | 124,556,004.14 | | Total Liabilities | 292,707,625.55 | 260,897,540.07 | | Total Equity Attributable to Parent Company Shareholders | 1,773,545,023.25 | 1,685,852,121.86 | | Total Owners' Equity | 1,837,427,315.37 | 1,736,272,501.66 | Consolidated Income Statement In the first three quarters of 2022, total operating revenue reached 482 million Yuan, up 15.0%, with total operating costs at 345 million Yuan, and selling expenses being the largest component at 231 million Yuan; net profit was 128 million Yuan, up 13.2%, and net profit attributable to parent company shareholders was 125 million Yuan, up 9.85% Key Items from Consolidated Income Statement (YTD Q3 2022) | Item | Jan-Sep 2022 (Yuan) | Jan-Sep 2021 (Yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 481,533,122.53 | 418,738,276.48 | | Total Operating Costs | 344,860,131.88 | 310,931,528.28 | | Selling Expenses | 230,974,978.98 | 214,253,846.51 | | R&D Expenses | 43,277,295.42 | 36,831,482.39 | | Total Profit | 153,483,627.16 | 130,607,394.27 | | Net Profit | 128,402,109.87 | 113,466,707.92 | | Net Profit Attributable to Parent Company Shareholders | 124,614,640.34 | 113,443,911.03 | Consolidated Cash Flow Statement In the first three quarters of 2022, net cash flow from operating activities significantly increased by 64.9% to 95.92 million Yuan from 58.15 million Yuan in the prior year; net cash outflow from investing activities was 49.85 million Yuan, and from financing activities was 40.22 million Yuan, with cash and cash equivalents at period end totaling 388 million Yuan Key Items from Consolidated Cash Flow Statement (YTD Q3 2022) | Item | Jan-Sep 2022 (Yuan) | Jan-Sep 2021 (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 95,923,327.44 | 58,154,839.61 | | Net Cash Flow from Investing Activities | -49,851,058.23 | 176,410,655.44 | | Net Cash Flow from Financing Activities | -40,217,933.65 | -38,879,540.20 | | Net Increase in Cash and Cash Equivalents | 5,554,369.82 | 195,694,114.70 | | Cash and Cash Equivalents at End of Period | 387,912,275.90 | 458,146,709.01 | Parent Company Financial Statements The parent company's financial statements show total assets of 1.984 billion Yuan and total liabilities of 233 million Yuan as of September 30, 2022; year-to-date operating revenue was 444 million Yuan and net profit 128 million Yuan, consistent with consolidated trends, reflecting core business stability Parent Company Balance Sheet As of September 30, 2022, the parent company's total assets were 1.984 billion Yuan, a 6.42% increase from year-start, with total owners' equity at 1.751 billion Yuan, indicating a robust asset structure Key Items from Parent Company Balance Sheet | Item | September 30, 2022 (Yuan) | December 31, 2021 (Yuan) | | :--- | :--- | :--- | | Total Assets | 1,983,602,763.19 | 1,863,924,157.75 | | Total Liabilities | 233,068,964.87 | 203,647,880.84 | | Total Owners' Equity | 1,750,533,798.32 | 1,660,276,276.91 | Parent Company Income Statement In the first three quarters of 2022, the parent company achieved operating revenue of 444 million Yuan, up 10.4%, and net profit of 128 million Yuan, up 13.5% Key Items from Parent Company Income Statement (YTD Q3 2022) | Item | Jan-Sep 2022 (Yuan) | Jan-Sep 2021 (Yuan) | | :--- | :--- | :--- | | Operating Revenue | 444,281,078.79 | 402,354,752.58 | | Operating Profit | 143,350,594.35 | 117,465,944.33 | | Total Profit | 152,131,714.11 | 128,375,253.08 | | Net Profit | 127,628,218.43 | 112,473,157.49 | Parent Company Cash Flow Statement In the first three quarters of 2022, net cash flow from operating activities for the parent company was 73.49 million Yuan, up 10.2%; net cash outflow from investing activities was 13.62 million Yuan, and from financing activities was 38.27 million Yuan, with cash and cash equivalents at period end totaling 233 million Yuan Key Items from Parent Company Cash Flow Statement (YTD Q3 2022) | Item | Jan-Sep 2022 (Yuan) | Jan-Sep 2021 (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 73,488,819.61 | 66,664,216.02 | | Net Cash Flow from Investing Activities | -13,621,374.80 | 36,433,560.80 | | Net Cash Flow from Financing Activities | -38,272,431.95 | -36,054,978.12 | | Cash and Cash Equivalents at End of Period | 232,530,124.00 | 292,256,939.92 |